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ABSTRACT
Purpose: This study aimed to investigate the expression of glutamine metabolism-
related protein in tumor and stromal compartments among the histologic subtypes 
of thyroid cancer.
Results: GLS1 and GDH expression in tumor and stromal compartments were the 
highest in AC than in other subtypes. Tumoral ASCT2 expression was higher in MC 
but lower in FC (p < 0.001). In PTC, tumoral GLS1 and tumoral GDH expression was 
higher in the conventional type than in the follicular variant (p = 0.043 and 0.001, 
respectively), and in PTC with BRAF V600E mutation than in PTC without BRAF V600E 
mutation (p<0.001). Stromal GDH positivity was the independent factor associated 
with short overall survival (hazard ratio: 21.48, 95% confidence interval: 2.178-211.8, 
p = 0.009).
Methods: We performed tissue microarrays with 557 thyroid cancer cases 
(papillary thyroid carcinoma [PTC]: 344, follicular carcinoma [FC]: 112, medullary 
carcinoma [MC]: 70, poorly differentiated carcinoma [PDC]: 23, and anaplastic 
carcinoma [AC]: 8) and 152 follicular adenoma (FA) cases. We performed 
immunohistochemical staining of glutaminolysis-related proteins (glutaminase 1 
[GLS1], glutamate dehydrogenase [GDH], and amino acid transporter-2 [ASCT-2]).
Conclusion: Glutamine metabolism-related protein expression differed among 
the histologic subtypes of thyroid cancer.
INTRODUCTION
We aimed to investigate the metabolism in thyroid 
cancer, especially glutamine metabolism in this study. The 
typical metabolism of malignant tumors can be explained 
with the Warburg effect. Most cancer cells produce energy 
not via a low rate of glycolysis based on oxidation of 
pyruvate in mitochondria but via a high rate of glycolysis 
based on lactic acid fermentation in cytosol [1]. Although 
aerobic glycolysis is one of the most important metabolic 
pathways, the flexibility of the metabolic system is a major 
obstacle in cancer treatment. Glutamine metabolism is a 
critical pathway in cancer cell metabolism [2]. In previous 
studies, cancer cells have been shown to metabolize 
glutamine more than other amino acids [3, 4]. Therefore, 
glutamine metabolism is an important metabolic 
phenotype of proliferating cancer cells, because it satisfies 
two important elements of the proliferating cancer cells, 
i.e., ATP production and supply of intermediates for 
macromolecular synthesis [2]. Furthermore, in glutamine 
metabolic pathway, the interaction between cancer cells 
and stromal cells is present. It was reported that ammonia, 
which is produced by tumor cell glutaminolysis migrates 
into the stroma, leading to increased autophagy of 
stromal cells. Consequently, glutamine was reported to be 
produced as the product of autophagy activity, travel back 
to tumor cells and utilized in glutamine metabolism [5-9].
The three proteins that play an important role 
in glutamine metabolic pathway are the amino acid 
transporter-2 (ASCT2), the transporter involved in the 
movement of glutamine into the cell that would be 
consumed by cancer cells [10]; glutaminase 1 (GLS1), 
the enzyme that converts glutamine to glutamate [11]; 
and glutamate dehydrogenase (GDH), the enzyme that 
converts glutamate to α-ketoglutarate to be used in the 
tricarboxylic acid cycle [12].
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Thyroid cancer is common, accounting for 
approximately 1.5% of the population [13]. The 
representative subtypes are papillary thyroid carcinoma 
(PTC), follicular carcinoma (FC), medullary carcinoma 
(MC), poorly differentiated carcinoma (PDC), and 
anaplastic carcinoma (AC). The cell origin, clinical 
manifestation, metastatic pattern, and clinical prognosis 
are different depending on the histologic subtype [14]. 
In previous studies of various tumors, differences in 
the expression of metabolism-related proteins were 
reported among the histological subtypes [15-18]. Thus, 
such differences can be expected in thyroid cancer as 
well; however, much research on this topic is required. 
Therefore, the purpose of this study was to investigate 
the expression of glutamine metabolism-related protein in 
tumor and stromal compartments depending on the subtype 
of thyroid cancer and its implications on patient prognosis.
RESULTS
Basal characteristics of patients with thyroid 
cancer
This study included 557 cases of thyroid cancer, 
as follows: 344 cases of PTC, 112 cases of FC, 70 cases 
of MC, 23 cases of PDC, and 8 cases of AC. The basal 
characteristics of the patients with PTC are shown in 
Supplementary Table 2. According to the histologic 
subtype of PTC, the samples were classified as the 
conventional type PTC (304 cases) and the follicular 
variant PTC (40 cases). A higher proportion of follicular 
variant PTC had expanding tumor margin (p = 0.002). 
Among the PTC cases, 238 cases (69.18%) had BRAF 
V600E mutation. A higher proportion of these cases had 
infiltrative tumor margin (p = 0.004) but the follicular 
variant occupied a lower proportion (p < 0.001) 
(Supplementary Table 2). FC included 99 cases of the 
minimally invasive type and 13 cases of the widely 
invasive type. The widely invasive type had a higher 
proportion of large tumor size (p = 0.040), vascular 
invasion (p = 0.028), extrathyroidal involvement (p < 
0.001), and distant metastasis (p = 0.003) (Supplementary 
Table 3). The basal characteristics of patients with MC, 
PDC, and AC are shown in Supplementary Table 4.
Expression of glutamine metabolism-related 
proteins in thyroid cancer
We investigated the expression of glutamine 
metabolism-related proteins in thyroid cancer. GLS1 and 
GDH were expressed in both tumor cells and stroma, 
but ASCT2 was expressed only in the tumor cells. The 
expression of glutamine metabolism-related proteins was 
different according to the histologic subtype of thyroid 
cancer (Figure 1 and Table 1), where the expression of 
tumoral GLS1 and tumoral GDH was higher in AC but 
lower in FC. Stromal GLS1 expression was observed only 
in AC, and stromal GDH expression was higher in AC. 
Figure 1: Expression of glutamine metabolism-related proteins according to the histologic subtype of thyroid cancer. 
The expression of tumoral GLS1 and tumoral GDH is higher in anaplastic carcinoma, but absent in follicular carcinoma; stromal GLS1 and 
stromal GDH expression are higher in anaplastic carcinoma. Tumoral ASCT2 expression is higher in medullary carcinoma, but absent in 
follicular carcinoma. The photos of GLS1, GDH, and ASCT2 expression are obtained from the same case of each subtype of thyroid cancer. 
GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino acid transporter-2.
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Tumoral ASCT2 expression was higher in MC but lower 
in FC (p < 0.001).
The results of the correlation analysis of the expression 
of GLS1, GDH, and ASCT showed significant quantitative 
correlation between GDH and GLS1 (r = 0.364), between 
GDH and ASCT2 (r = 0.174), between GLS1 and ASCT2 (r 
= 0.213), and between GDH(S) and GLS1(S) (r = 0.403; all 
p < 0.001; Table 2). Furthermore, we performed a correlation 
analysis between the subtype of thyroid cancer with the 
expression of GLS1, GDH, and ASCT. As a result, in PTC, 
statistically significant correlation was shown between GLS1 
and GDH (r=0.328, p<0.001), between GLS1 and ASCT2 
(r=0.251, p<0.001), and between GDH and ASCT2 (r=0.165, 
p=0.002). The same result was also shown in FC, with a 
significant correlation between GLS1 and GDH (r=0.373, 
p<0.001), between GLS1 and ASCT2 (r=0.246, p=0.010), 
and between GDH and ASCT2 (r=0.190, p=0.046). In 
addition, the correlation between GLS1 and GDH (r=0.030, 
p=0.012) was shown in MC and between GLS1 and ASCT2 
(r=0.476, p=0.025) in PDC were noted.
Expression of glutamine metabolism-related 
proteins according to the histologic subtype of 
thyroid cancer
We investigated the expression of glutamine 
metabolism-related proteins according to the histologic 
subtype of thyroid cancer. First, in PTC, tumoral GLS1 and 
tumoral GDH expression was higher in the conventional 
type than in the follicular variant (p = 0.024 and p < 
0.001, respectively) (Figure 2 and Table 3). In addition, 
PTC with the BRAF V600E mutation showed higher 
expression of tumoral GLS1, tumoral GDH, and tumoral 
ASCT2 (p < 0.001) (Figure 3 and Table 3). Secondly, in 
follicular neoplasms, tumoral GLS1 and tumoral GDH 
expression was higher in FC than in FA (p = 0.021 and 
0.001, respectively) (Figure 4 and Table 4). Thirdly, in FC, 
the expression of glutamine metabolism-related proteins 
showed no significant difference between the minimally 
invasive type and the widely invasive type (Table 5).
Correlation between the expression of 
glutamine metabolism-related proteins and 
clinicopathologic factors
We investigated the correlation between the 
expression of glutamine metabolism-related proteins 
and the clinicopathologic factors in patients with thyroid 
cancer except for AC. Tumoral GDH positivity was 
associated with extrathyroidal extension, small tumor size, 
and lymph node metastasis (p < 0.001 for all). In PTC, 
the expression of tumoral GLS1 and tumoral GDH was 
associated with an infiltrative tumor margin (p = 0.011 and 
0.002, respectively) (Figure 5).
Table 1: Expression of glutamine metabolism-related proteins according to the histologic subtype of thyroid cancer
Parameters TotalN= 557(%)
PTC
n= 344(%)
FC
n= 112(%)
MC
n= 70(%)
PDC
n= 23(%)
AC
n= 8(%) p-value
GLS1 (T) <0.001
 Negative 247 (44.3) 141 (41.0) 70 (62.5) 27 (38.6) 9 (39.1) 0 (0.0)
 Positive 310 (55.7) 203 (59.0) 42 (37.5) 43 (61.4) 14 (60.9) 8 (100.0)
GLS1 (S) <0.001
 Negative 554 (99.5) 344 (100.0) 112 (100.0) 70 (100.0) 23 (100.0) 5 (62.5)
 Positive 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 3 (37.5)
GDH (T) <0.001
 Negative 105 (18.9) 43 (12.5) 48 (42.9) 11 (15.7) 3 (13.0) 0 (0.0)
 Positive 452 (81.1) 301 (87.5) 64 (57.1) 59 (84.3) 20 (87.0) 8 (100.0)
GDH (S) <0.001
 Negative 549 (98.6) 341 (99.1) 112 (100.0) 70 (100.0) 22 (95.7) 4 (50.0)
 Positive 8 (1.4) 3 (0.9) 0 (0.0) 0 (0.0) 1 (4.3) 4 (50.0)
ASCT2 (T) <0.001
 Negative 459 (82.4) 289 (84.0) 103 (92.0) 43 (61.4) 17 (73.9) 7 (87.5)
 Positive 98 (17.6) 55 (16.0) 9 (8.0) 27 (38.6) 6 (26.1) 1 (12.5)
PTC; papillary thyroid carcinoma, FC; follicular carcinoma, MC; medullary carcinoma, PDC; poorly differentiated carcinoma, 
AC; anaplastic carcinoma, GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino acid transporter-2
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Table 2: Correlation among the expressions of glutamine metabolism-related proteins
Parameters GLS1 GDH ASCT2 GLS1 (S)
GLS1
 Correlation coefficient
 p-value
GDH
 Correlation coefficient 0.364
 p-value <0.001
ASCT2
 Correlation coefficient 0.213 0.174
 p-value <0.001 <0.001
GLS1 (S)
 Correlation coefficient 0.066 0.035 -0.034
 p-value 0.121 0.403 0.423
GDH (S)
 Correlation coefficient 0.077 0.058 0.023 0.403
 p-value 0.068 0.170 0.580 <0.001
Figure 2: Expression of glutamine metabolism-related proteins according to the histologic subtype of papillary thyroid 
cancer (PTC). Tumoral GLS1 and tumoral GDH expression are higher in the conventional type of PTC than in the follicular variant of 
PTC. GLS1; glutaminase 1, GDH; glutamate dehydrogenase
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Influence of the expression of glutamine 
metabolism-related proteins on patient  
prognosis
We investigated the effect of the expression of 
glutamine metabolism-related proteins on prognosis 
through univariate analysis and multivariate Cox analysis. 
In univariate analysis, shorter disease-free survival was 
associated with stromal GDH expression (p < 0.001) 
(Table 6). In multivariate Cox analysis, shorter disease-
free survival was associated with lymph node metastasis 
(hazard ratio: 6.021, 95% confidence interval [CI]: 
1.352-26.82, p = 0.019), and shorter overall survival was 
associated with old age (≥45 years, hazard ratio: 25.26, 
95% CI: 3.047-209.4, p = 0.003), lymph node metastasis 
(hazard ratio: 4.466, 95% CI: 1.352-14.76, p = 0.014) 
and stromal GDH positivity (hazard ratio: 21.48, 95% CI: 
2.178-211.8, p = 0.009) (Table 7).
DISCUSSION
In this study, GLS1 and GDH showed higher 
expression in both tumor cells and stroma in AC, but it was 
lower in FC. In general, the higher tumor aggressiveness, 
the higher metabolic activity and glutamine metabolism-
related protein - GLS1, GDH, and ASCT2 - has been 
reported to be associated with tumor aggressive factor in 
other tumors [19-21]. There are several possible reasons 
for the higher expression of glutamine metabolism-related 
proteins in AC than in other subtypes: different tumor cell 
proliferative activity, high metastatic potential, and the 
impact of oncogenic driver. AC should show the highest 
metabolic activity, as metabolic activity was reported to be 
more than three times greater in AC than in other subtypes 
of thyroid cancer [22]. AC also has high metastatic 
potential, with distant metastasis reported at diagnosis 
in 46% of cases [23], and in tumor metastasis, glutamine 
metabolism has been reported to play an important role 
[24]. Finally, unlike other subtypes of thyroid cancer, AC 
has been shown to have increased HER-2 expression [25] 
and activation of Wnt β-catenin pathway [26]. HER-2 and 
β-catenin pathway have been reported to be associated 
with increased glutamine metabolism [27, 28].
One interesting point is that in PDC, a highly 
aggressive type of tumor similar to AC, the expression 
of GLS1 and GDH was not significantly higher than that 
of other subtypes, unlike AC. The different expressions 
in PDC and AC can be explained by the genetic change 
between the two subtypes. In previous studies, one major 
difference was that TP53 mutation, which is known to be 
associated with metabolism, was shown in 26% of PDC 
samples as opposed to 60% of AC samples [29-31]. Glut-1 
and Glut-4, key proteins in glycolysis, were reported to 
be inhibited by wild type p53 [32]. Considering that TP53 
mutation neutralizes this interaction, AC was reported 
to exhibit TP53 and Glut-1 overexpression [33]. An 
Table 3: Expression of glutamine metabolism-related proteins according to the histologic subtype and BRAF V600E 
mutation status of papillary thyroid carcinoma
Parameters Total
N=344 (%)
Histologic subtype
p-value
BRAF V600E mutation 
status
p-value
Conventional 
type
n= 304 (%)
Follicular 
variant
n= 40 (%)
No mutation
n= 106 (%)
Mutation
n= 238 (%)
GLS1 (T) 0.024 <0.001
 Negative 141 (41.0) 118 (38.8) 23 (57.5) 58 (54.7) 83 (34.9)
 Positive 203 (59.0) 186 (61.2) 17 (42.5) 48 (45.3) 155 (65.1)
GDH (T) <0.001 <0.001
 Negative 43 (12.5) 28 (9.2) 15 (37.5) 26 (24.5) 17 (7.1)
 Positive 301 (87.5) 276 (90.8) 25 (62.5) 80 (75.5) 221 (92.9)
GDH (S) 1.000 0.246
 Negative 341 (99.1) 301 (99.0) 40 (100.0) 106 (100.0) 235 (98.7)
 Positive 3 (0.9) 3 (1.0) 0 (0.0) 0 (0.0) 3 (1.3)
ASCT2 (T) 0.041 <0.001
 Negative 289 (84.0) 251 (82.6) 38 (95.0) 102 (96.2) 187 (78.6)
 Positive 55 (16.0) 53 (17.4) 2 (5.0) 4 (3.8) 51 (21.4)
GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino acid transporter-2
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association between TP53 mutation and metabolism was 
also shown, potentially explaining the different GLS1 
and GDH expressions in PDC and AC in this study. 
Furthermore, p53 immunohistochemical staining was 
performed in PDC and AC to evaluate the association 
with the expressions of glutamine metabolism-related 
proteins. As a result, p53 positivity showed an association 
with stromal GDH expression (p=0.029), tumoral 
GLS1 (p=0.054), and stromal GLS1 (p=0.055), further 
supporting the relationship between p53 positivity and 
the expressions of glutamine metabolism-related proteins 
(Supplementary Table 5). Further research using next-
generation sequencing analyzed the genetic alterations 
between PDC and AC. As a result, several genetic 
changes were coincided in PDC and AC. However, each 
type has been reported as having its own specific genetic 
background [34].
In particular, the expression in AC was high 
in stroma as well as in tumor cells. In breast cancer, 
glutamine metabolism-related protein expression in 
Figure 3: Expression of glutamine metabolism-related proteins according to the BRAF V600E mutation status in 
papillary thyroid cancer. Papillary thyroid cancer with the BRAF V600E mutation shows higher expression of tumoral GLS1, tumoral 
GDH, and tumoral ASCT2. GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino acid transporter-2
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stroma was similar to such expression in tumor cells 
[21]. Metabolic interaction could exist between tumoral 
and stromal cells, such as cancer-associated fibroblasts, 
according to the cancer types [7, 35-38]. In addition, 
the interaction has been reported to exist in glutamine 
metabolic pathway. Previous studies have shown a 
vicious cycle wherein ammonia (a byproduct of tumor 
cell glutaminolysis) diffuses into the stroma, induces 
autophagy, produces glutamine as a product of autophagy 
activity, and is passed back to tumor cells [5-9]. In one 
study, when the MCF-7 cell line was co-cultured with 
fibroblasts, the expression of GLS, GDH, and SLC6A14 
(glutamine importer) in tumor cells increased and 
glutamine neosynthesis decreased compared to when the 
cell line was cultured alone. The transmission of glutamine 
from stromal cells to tumor cells has demonstrated, 
and in the case, the cell proliferation has reported to be 
increased [9]. Therefore, the interaction between tumor 
cells and stromal cells in the glutamine metabolic pathway 
promotes tumor cell proliferation and growth. The 
increased glutamine metabolic activity in tumor cells and 
stromal cells in AC contributes to tumor aggressiveness. 
In addition, tumoral GLS1 and GDH expression was the 
highest in conventional type PTC followed by follicular 
variant PTC, FC, and FA; therefore, GLS1 and GDH were 
proven to show lower expression with more follicular 
differentiation. As the expression of metabolic pathway-
related protein such as Glut-1 has been reported to be 
Figure 4: Expression of glutamine metabolism-related proteins in follicular neoplasms. Tumoral GLS1 and tumoral GDH 
expression are higher in follicular carcinoma than in follicular adenoma. GLS1; glutaminase 1, GDH; glutamate dehydrogenase
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different according to tumor differentiation in various 
human cancers [39, 40], such a phenomenon in thyroid 
cancer can seem possible.
PTC with the BRAF V600E mutation showed 
a higher expression of glutamine metabolism-related 
proteins. The BRAF V600E mutation is associated with 
extra-thyroidal extension, advanced TNM stage, lymph 
node metastasis, multifocality, and recurrence in a meta-
analysis study [41]. Because PTC with the BRAF V600E 
mutation has aggressive tumor biology, it can be suggested 
that it shows higher expression of glutamine metabolism-
related proteins. In addition, PTC with the BRAF V600E 
mutation has been reported to show increased glucose 
metabolism [42]. One possible mechanism is that the 
BRAF mutation is associated with the activation of 
mitogen-activated protein kinase downstream molecules 
such as c-MYC and HIF-1a; therefore, glucose metabolism 
increases. Furthermore, cell proliferation in melanoma 
cells with BRAF mutations has been reported to rely on 
glutamine metabolism [43]. Accordingly, the association 
between PTC with the BRAF V600E mutation and 
increased glutamine metabolism is supported.
The expression of ASCT2 was higher in MC. 
The association with the MYC gene can be considered a 
possible mechanism. In previous studies, MYC expression 
has been reported in MC [44-46]. The MYC gene has been 
Table 4: Expression of glutamine metabolism-related proteins in follicular neoplasms
Parameters TotalN=264 (%)
FA
n=152 (%)
FC
n=112 (%) p-value
GLS1 (T) 0.021
 Negative 185 (70.1) 115 (75.7) 70 (62.5)
 Positive 79 (29.9) 37 (24.3) 42 (37.5)
GDH (T) 0.001
 Negative 144 (54.5) 96 (63.2) 48 (42.9)
 Positive 120 (45.5) 56 (36.8) 64 (57.1)
ASCT2 (T) 0.156
 Negative 249 (94.3) 146 (96.1) 103 (92.0)
 Positive 15 (5.7) 6 (3.9) 9 (8.0)
FA; follicular adenoma, FC: follicular carcinoma, GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino 
acid transporter-2
Table 5: Expression of glutamine metabolism-related proteins according to the histologic subtype of follicular 
carcinoma (FC)
Parameters TotalN=112 (%)
FC, minimally 
invasive type
n=99 (%)
FC, widely invasive 
type
n=13 (%)
p-value
GLS1 (T) 0.493
 Negative 70 (62.5) 63 (63.6) 7 (53.8)
 Positive 42 (37.5) 36 (36.4) 6 (46.2)
GDH (T) 0.394
 Negative 48 (42.9) 41 (41.4) 7 (53.8)
 Positive 64 (57.1) 58 (58.6) 6 (46.2)
ASCT2 (T) 0.257
 Negative 103 (92.0) 90 (90.9) 13 (100.0)
 Positive 9 (8.0) 9 (9.1) 0 (0.0)
FC: follicular carcinoma, GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino acid transporter-2
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reported to increase the expression of ASCT2 by binding 
to the promoter element of the glutamine transporter 
[47]; hence, the higher ASCT2 expression in MC can be 
explained.
Stromal GDH expression was an independent 
prognostic factor in thyroid cancer. In previous studies, 
GDH expression was shown to be associated with poor 
prognosis in colon cancer [48], carcinoma of unknown 
primary [49], and breast phyllodes tumor [20]. The 
compartment with GDH expression differed depending on 
the tumor. Stromal GDH expression in breast phyllodes 
tumors [20] and tumoral GDH expression in carcinoma of 
unknown primary [49] have been reported to be associated 
with patient prognosis. An analysis of colon cancer did not 
divide the compartment between tumor cells and stroma; 
therefore, GDH expression could not be evaluated in this 
case [48]. Likewise, the influence of GDH on prognosis 
differs according to the expressed compartments.
In this study, we showed positive correlation 
between the expression of GLS1, GDH and ASCT2. This 
positive correlation was observed when targeting not only 
all subtypes of thyroid cancer but also PTC and FC and 
a partial correlation was also shown in MC and PDC. It 
suggests the role of GLS1, GDH, and ASCT2 evaluation 
by immunohistochemical staining could possibly reflect 
the glutamine metabolism activity.
The results suggest that the glutamine metabolism 
pathway can be used as a possible target for therapy 
in thyroid cancer. The potential candidates for target 
therapy among thyroid cancer are radioiodine refractory 
differentiated thyroid cancer, PDC, AC, and MC. 
Targeted therapies that is currently used in thyroid cancer 
are tyrosine kinase inhibitors (TKIs) and monoclonal 
antibodies (mAbs), which inhibits the tyrosine kinase 
activity that is essential in the pathogenesis of thyroid 
cancer [50]. However, clinical trials regarding TKIs and 
mAbs had shown unsatisfactory results, only with a partial 
response rate ranging from 2 to 45% [51-54]. This might 
be attributable by the drug resistance, cytostatic action of 
TKIs and drug toxicity [50], necessitating novel target 
agent to overcome these limitations. The possible strategy 
is to reduce glutamine metabolic enzyme activity or reduce 
glutamine uptake. GLS1 inhibitors including BPTES 
[55-57], 968 [58-60], and CB-839 [61, 62] are under 
preclinical and clinical trials for the treatment of various 
tumors. BenSer as an ASCT2 inhibitor has been reported 
to inhibit the proliferation of melanoma cells [63]. In 
particular, radioiodine refractory thyroid tumor might be 
suitable for targeted therapy since it shows positive scan 
in 18FDG-PET [64]. Therefore, the inhibition of metabolic 
pathway might be used as an alternative effective 
therapeutic option, which requires further studies.
In conclusion, the expression of glutamine 
metabolism-related proteins in thyroid cancer was found 
to differ according to histologic subtype. GLS1 and GDH 
expression was high in both tumor cells and stroma of AC. 
Figure 5: Correlation between the expressions of glutamine metabolism-related proteins and clinicopathologic factors 
in thyroid cancer and papillary thyroid carcinoma.
Oncotarget53637www.impactjournals.com/oncotarget
Table 6: Univariate analysis of the influence of glutamine-related protein expression in thyroid cancer on disease-free 
and overall survival by the log-rank test
Parameter
Number of 
patients*/
recurrence/death
Disease-free survival Overall survival
Mean survival
(95% CI) months P-value
Mean survival
(95% CI) months P-value
GLS1 (T) 0.141 0.938
 Negative 247/22/13 101 (98-105) 106 (103-108)
 Positive 302/17/17 106 (103-108) 106 (103-108)
GDH (T) 0.470 0.896
 Negative 105/9/5 101 (96-107) 106 (103-110)
 Positive 444/30/25 104 (102-107) 106 (104-108)
GDH (S) 0.110 <0.001
 Negative 545/38/28 104 (102-106) 107 (105-108)
 Positive 4/1/2 68 (24-112) 54 (13-95)
ASCT2 (T) 0.677 0.217
 Negative 452/33/22 104 (101-106) 107 (105-109)
 Positive 97/6/8 103 (98-108) 102 (96-107)
*cases of AC were excluded. GLS1; glutaminase 1, GDH; glutamate dehydrogenase, ASCT2; amino acid transporter-2
Table 7: Multivariate analysis of factors influencing survival of patients with thyroid cancer *
Included parameters
Disease-free survival Overall survival
Hazard 
ratio 95% CI P-value
Hazard 
ratio 95% CI P-value
Age (years) 0.631 0.003
 <45 versus ≥45 1.263 0.488-3.272 25.26 3.047-209.4
Sex 0.668 0.402
 Male versus Female 1.265 0.433-3.690 1.564 0.550-4.449
Tumor size (cm) 0.798 0.402
 ≤2.0 versus >2.0 1.147 0.400-3.288 1.564 0.550-4.449
Tumor extension 0.352 0.504
Intrathyroidal versus Extrathyroidal 0.631 0.239-1.663 0.688 0.229-2.061
LN metastasis 0.019 0.014
 No versus Yes 6.021 1.352-26.82 4.466 1.352-14.76
GLS1 (T) 0.273 0.422
 Negative versus positive 0.587 0.226-1.522 0.676 0.261-1.757
GDH (S) n/a 0.009
 Negative versus positive n/a n/a 21.48 2.178-211.8
*cases of AC were excluded. GLS1; glutaminase 1, GDH; glutamate dehydrogenase
Oncotarget53638www.impactjournals.com/oncotarget
ASCT2 expression was high in MC. In addition, tumoral 
GLS1 and tumoral GDH expression was high in PTC 
with the BRAF V600E mutation. Therefore, the glutamine 
metabolism pathway may be a possible target for therapy 
in thyroid cancer.
MATERIALS AND METHODS
Patient selection
For PTC, we included patients who underwent 
surgery at Severance Hospital between January 2012 
and December 2013. For other subtypes, we included 
patients who underwent surgery at Severance Hospital 
between January 2000 and December 2014. Patients 
treated with neoadjuvant chemotherapy were excluded. 
This study was approved by the Institutional Review 
Board (IRB) of Yonsei University Severance Hospital. 
Consent forms of patients were exempt by IRB. All cases 
were retrospectively reviewed by a thyroid pathologist 
(Koo JS), and histologic review was performed by using 
hematoxylin and eosin-stained slides. Clinicopathologic 
data were obtained from the patients’ medical records; they 
included age at diagnosis, disease recurrence, metastasis, 
current status, and length of follow-up. The tumor size, 
tumor margin (infiltrative or expanding), extent (confined 
to the thyroid parenchyma or with extrathyroidal spread), 
and the status of metastatic lymph nodes were also noted 
from review of the slides and the surgical pathology 
reports.
Tissue microarray analysis
Representative areas were selected on hematoxylin-
eosin-stained slides, and the corresponding spot was 
marked on the surface of the matching paraffin block. 
Core biopsies (3 mm) were taken from selected areas and 
placed into a 6 × 5 recipient block. Two tissue cores were 
extracted from each case to minimize extraction bias. 
Each tissue core was assigned a unique tissue microarray 
location number that was linked to a database containing 
other clinicopathologic data.
Immunohistochemistry
Antibodies used for immunohistochemistry are listed 
in Supplementary Table 1. All immunohistochemistry was 
performed on formalin-fixed, paraffin-embedded tissue 
sections by using an automatic immunohistochemistry 
staining device (Benchmark XT, Ventana Medical System, 
Tucson, AZ, USA). Briefly, 5-μm-thick formaldehyde-
fixed paraffin-embedded tissue sections were transferred 
onto adhesive slides and dried at 62°C for 30 minutes. 
Standard heat epitope retrieval was performed for 30 
minutes in ethylene diamine tetraacetic acid, pH 8.0, 
in the autostainer. The samples were then incubated 
with primary antibodies. After incubation with primary 
antibodies, the sections were subsequently incubated with 
biotinylated anti-mouse immunoglobulins, peroxidase-
labeled streptavidin (LSAB kit, DakoCytomation), and 
3,3’-diaminobenzidine. Negative control samples were 
processed without the primary antibody. Positive control 
tissue was used as per the manufacturer’s recommendation. 
All slides were counterstained with Harris hematoxylin.
Interpretation of immunohistochemical staining
Immunohistochemical markers were assessed 
under light microscopy with x200 magnification in the 
entire core of the tissue microarray. The expression of 
glutamine metabolism-related proteins was evaluated 
semi-quantitatively according to a previously reported 
method [65]. Tumoral and stromal staining was assessed 
as 0: negative or weak immunostaining in <1% of the 
tumor/stroma, 1: focal expression in 1-10% of the tumor/
stroma, 2: positive in 11%-50% of the tumor/stroma, and 
3: positive in 51%-100% of the tumor/stroma. The score 
of ≥2 was defined as positive. BRAF V600E staining was 
considered positive when more than 20% tumor cells 
were positive [66]. Immunohistochemical staining was 
interpreted independently by two pathologists (KHM and 
KJS). In cases of discrepancy between the pathologists, 
the final result was determined through discussion under 
the multi-view microscopy.
Statistical analysis
Data were analyzed using SPSS for Windows, 
Version 12.0 (SPSS Inc., Chicago, IL, USA). For 
determination of statistical significance, the Student t-
test and Fisher exact tests were used for continuous 
and categorical variables, respectively. The correlation 
between the expression of GLS1, GDH, and ASCT was 
analyzed using Kendall’s method. In the case of analyzing 
data with multiple comparisons, a corrected p-value with 
the application of the Bonferroni multiple comparison 
procedure was used. Statistical significance was set at p < 
0.05. Kaplan-Meier survival curves and log-rank statistics 
were employed to evaluate time to tumor recurrence and 
overall survival. Multivariate regression analysis was 
performed using the Cox proportional hazards model.
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